Répertoire du corps professoral

Biology and Control of Zoonotic and Pandemic Respiratory Viruses
Programme: Fonds des leaders John-R.-Evans (FLJR)
Organisme(s) subventionnaire(s): Ministère de la Santé et des Services sociaux, Fondation Canadienne pour l'innovation (La), Université Laval - Fonds internes
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 août 2025 au 31 août 2027

Fond de démarrage-Nouveau chercheur
Programme: Fonds de démarrage
Organisme(s) subventionnaire(s): Fondation du CHU de Québec, CHU de Québec – Université Laval – CHUL
Type de financement: Subvention
Établissement tête: Université Laval
Du 27 mai 2024 au 31 mars 2027

Chaire d’excellence de recherche du Canada on Biology and Control of Zoonotic and Pandemic Respiratory Viruses
Programme: Programme de chaires d'excellence en recherche du Canada
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 septembre 2023 au 26 mai 2033

Financements des 2 dernières années

Is treatment with a combination of licensed influenza antivirals superior to monotherapy for highly pathogenic H5N1 influenza virus from cattle?
Programme: Subvention catalyseur : Recherche « Une seule santé » sur la grippe aviaire
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 septembre 2024 au 31 août 2025

Aerosol Infection Research: Better mOdels to Reduce iNdoor Exposure (AIRBORNE)
Programme: 2021 Coronavirus Research Response – Covid-19 Treatment Access and Public Health Activities
Organisme(s) subventionnaire(s): Medical Research Future Fund
Type de financement: Subvention
Établissement tête: The University of Melbourne
Du 1 juin 2022 au 31 janvier 2026

Simran Srivastava, Stage postdoctoral en médecine

Brown Bulloch, Maîtrise en microbiologie-immunologie - avec mémoire

Publications des 5 dernières années

Reconciliation of titer differences between SARS-CoV-2 neutralizing antibody assays Journal of Virology, 2026/09/22. Eva Stadler, Francesca Mordant, Matthew Gartner, Steffen S. Docken, Miles P. Davenport, David S. Khoury, Kanta Subbarao. DOI 10.1128/jvi.00823-26

The Platform trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters in immunocompetent adults VACCINE, 2026. DOI 10.1016/J.VACCINE.2026.128970

Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18-55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trial JOURNAL OF INFECTIOUS DISEASES, 2026. DOI 10.1093/INFDIS/JIAF568

SARS-CoV-2 infection patterns and immune responses by fourth-dose COVID-19 vaccination status AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH, 2026.

Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59 NPJ VACCINES, 2026. DOI 10.1038/S41541-025-01355-Y

PICOBOO: the immunogenicity of COVID-19 booster vaccines in individuals >12 years old AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH, 2026.

Nomenclature for Tracking of Genetic Variation of Seasonal Influenza Viruses INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2026. DOI 10.1111/IRV.70230

Influenza vaccine responses differ between young children previously exposed to influenza antigens via infection versus vaccination COMMUNICATIONS MEDICINE, 2026. DOI 10.1038/S43856-026-01610-W

Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia JOURNAL OF INFECTION, 2026. DOI 10.1016/J.JINF.2026.106727

Delivery of monoclonal antibodies using mRNA lipid nanoparticles confers protection against SARS-CoV-2 and influenza MOLECULAR THERAPY NUCLEIC ACIDS, 2026. DOI 10.1016/J.OMTN.2026.102873

Antibody responses following COVID-19 vaccination and breakthrough infections in naïve and convalescent individuals suggest imprinting to the ancestral strain of SARS-CoV-2 MBIO, 2026. DOI 10.1128/MBIO.03221-25

AIRBORNE INFECTIOUS SARS-COV-2 IN RECENTLY DIAGNOSED PATIENTS: INSIGHTS FOR HOSPITAL SAFETY INTERNAL MEDICINE JOURNAL, 2026.

Human guanylate-binding protein (GBP) 1 inhibits replication of severe acute respiratory syndrome coronavirus 2 Journal of Virology, 2025/10/23. Rubaiyea Farrukee, Francesca Mordant, Charley Mackenzie-Kludas, Dejan Mesner, Masahiro Yamomoto, Clare Jolly, Andrew G. Brooks, Kanta Subbarao, Sarah L. Londrigan, Patrick C. Reading. DOI 10.1128/jvi.00823-25

Ultraviolet radiation vs air filtration to mitigate virus laden aerosol in an occupied clinical room JOURNAL OF HAZARDOUS MATERIALS, 2025. DOI 10.1016/J.JHAZMAT.2025.137211

The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose JOURNAL OF INFECTION, 2025. DOI 10.1016/J.JINF.2025.106447

Severe acute respiratory syndrome coronavirus-2 shedding in exhaled material: a systematic review EPIDEMIOLOGY & INFECTION, 2025. DOI 10.1017/S0950268825100174

Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2023 COMMUNICABLE DISEASES INTELLIGENCE, 2025. DOI 10.33321/CDI.2025.49.028

Potent neutralising monoclonal antibodies targeting the spike of NL63 coronavirus NPJ VIRUSES, 2025. DOI 10.1038/S44298-025-00116-X

Memory B cell proliferation drives differences in neutralising responses between ChAdOx1 and BNT162b2 SARS-CoV-2 vaccines FRONTIERS IN IMMUNOLOGY, 2025. DOI 10.3389/FIMMU.2025.1487066

High-stability, clamp-free soluble Sarbecovirus spike trimers and their potential for pan-Sarbecovirus vaccine development. bioRxiv, 2025. DOI 10.1101/2025.09.14.676173

Genetic markers of enhanced functional antibody responses to COVID-19 vaccination VACCINE, 2025. DOI 10.1016/J.VACCINE.2025.127379

Effect of Bacille Calmette-Guérin vaccination on immune responses to SARS-CoV-2 and COVID-19 vaccination CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2025. DOI 10.1002/CTI2.70023

Dysregulated inflammation in solid tumor malignancy patients shapes polyfunctional antibody responses to COVID-19 vaccination NPJ VACCINES, 2025. DOI 10.1038/S41541-025-01268-W

De novo administration of antiviral monoclonal antibodies against SARS-CoV-2 or influenza using mRNA lipid nanoparticles bioRxiv, 2025. DOI 10.1101/2025.07.23.666463

Contemporary seasonal human coronaviruses display differences in cellular tropism compared to laboratory-adapted reference strains JOURNAL OF VIROLOGY, 2025. DOI 10.1128/JVI.00684-25

Antibody responses against influenza A decline with successive years of annual influenza vaccination NPJ VACCINES, 2025. DOI 10.1038/S41541-024-01057-X

Modelling the synergy between single-occupancy and PPE in controlling COVID-19 outbreaks on hospital wards 2024/12/26. Cameron Zachreson, Robyn Schofield, Caroline Marshall, Marion Kainer, Kirsty Buising, Jason Monty, Sheena Sullivan, Kanta Subbarao, Nicholas Geard. DOI 10.1101/2024.12.23.24319413

Implications of the apparent extinction of B/Yamagata-lineage human influenza viruses npj Vaccines, 2024/11/16. Ian G. Barr, Kanta Subbarao. DOI 10.1038/s41541-024-01010-y

The flavonoid quercetin decreases ACE2 and TMPRSS2 expression but not SARS-CoV-2 infection in cultured human lung cells BIOFACTORS, 2024. DOI 10.1002/BIOF.2084

The Platform trial In COVID-19 vaccine priming and BOOsting (PICOBOO) booster vaccination substudy protocol TRIALS, 2024. DOI 10.1186/S13063-024-08456-4

The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old JOURNAL OF INFECTION, 2024. DOI 10.1016/J.JINF.2024.106346

The Platform Trial I n CO VID-19 Priming and BOO sting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old JOURNAL OF INFECTION, 2024. DOI 10.1016/J.JINF.2024.106286

Speci fi c and off-target immune responses following COVID-19 vaccination with ChAdOx1-S and BNT162b2 vaccines - an exploratory sub-study of the BRACE trial EBIOMEDICINE, 2024. DOI 10.1016/J.EBIOM.2024.105100

Kidney organoids reveal redundancy in viral entry pathways during ACE2-dependent SARS-CoV-2 infection JOURNAL OF VIROLOGY, 2024. DOI 10.1128/JVI.01802-23

Inno4Vac Workshop Report Part 1: Controlled Human Influenza Virus Infection Model (CHIVIM) Strain Selection and Immune Assays for CHIVIM Studies, November 2021, MHRA, UK INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2024. DOI 10.1111/IRV.70014

Human coronavirus OC43 nanobody neutralizes virus and protects mice from infection JOURNAL OF VIROLOGY, 2024. DOI 10.1128/JVI.00531-24

Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): study protocol for an adaptive randomised controlled clinical trial TRIALS, 2024. DOI 10.1186/S13063-024-08315-2

Antigenic drift and subtype interference shape A(H3N2) epidemic dynamics in the United States ELIFE, 2024. DOI 10.7554/ELIFE.91849

When to update COVID-19 vaccine composition NATURE MEDICINE, 2023. DOI 10.1038/S41591-023-02220-Y

What HaveWe Learned by Resurrecting the 1918 Influenza Virus? ANNUAL REVIEW OF VIROLOGY, 2023. DOI 10.1146/ANNUREV-VIROLOGY-111821-104408

Virology under the Microscope-a Call for Rational Discourse MSPHERE, 2023. DOI 10.1128/MSPHERE.00034-23

The re-emergence of influenza following the COVID-19 pandemic in Victoria, Australia, 2021 to 2022 EUROSURVEILLANCE, 2023. DOI 10.2807/1560-7917.ES.2023.28.37.2300118

The re-emergence of influenza following the COVID-19 pandemic in Victoria, Australia Eurosurveillance, 2023. DOI 10.1101/2023.04.02.23288053

Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccines VACCINE, 2023. DOI 10.1016/J.VACCINE.2023.10.034

Role of the viral polymerase during adaptation of influenza A viruses to new hosts CURRENT OPINION IN VIROLOGY, 2023. DOI 10.1016/J.COVIRO.2023.101363

Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities NATURE IMMUNOLOGY, 2023. DOI 10.1038/S41590-023-01508-Y

Robust SARS-CoV-2 T cell responses with common TCRab motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells CELL REPORTS MEDICINE, 2023. DOI 10.1016/J.XCRM.2023.101017

Respiratory viruses: New frontiers-a Keystone Symposia report ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 2023. DOI 10.1111/NYAS.14958

Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2022 COMMUNICABLE DISEASES INTELLIGENCE, 2023. DOI 10.33321/CDI.2023.47.43

Predicting the efficacy of variant-modified COVID-19 vaccine boosters NATURE MEDICINE, 2023. DOI 10.1038/S41591-023-02228-4

Parallel use of human stem cell lung and heart models provide insights for SARS-CoV-2 treatment STEM CELL REPORTS, 2023. DOI 10.1016/J.STEMCR.2023.05.007

Mammalian infections with highly pathogenic avian influenza viruses renew concerns of pandemic potential JOURNAL OF EXPERIMENTAL MEDICINE, 2023. DOI 10.1084/JEM.20230447

Macrophage ACE2 is necessary for SARS-CoV-2 replication and subsequent cytokine responses that restrict continued virion release SCIENCE SIGNALING, 2023. DOI 10.1126/SCISIGNAL.ABQ1366

Long-term safety and immunogenicity of an MF59- adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or >56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial EBIOMEDICINE, 2023. DOI 10.1016/J.EBIOM.2023.104842

Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster EBIOMEDICINE, 2023. DOI 10.1016/J.EBIOM.2023.104878

Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variants ISCIENCE, 2023. DOI 10.1016/J.ISCI.2023.106256

Immune profiling of SARS-CoV-2 infection during pregnancy reveals NK cell and ?? T cell perturbations JCI INSIGHT, 2023. DOI 10.1172/JCI.INSIGHT.167157

Detection of Influenza in Managed Quarantine in Australia and the Estimated Risk of Importation CLINICAL INFECTIOUS DISEASES, 2023. DOI 10.1093/CID/CIAC648

Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection EMERGING INFECTIOUS DISEASES, 2023. DOI 10.3201/EID2902.221422

Core protocol for the adaptive Platform Trial In COVID-19 Vaccine priming and BOOsting (PICOBOO) TRIALS, 2023. DOI 10.1186/S13063-023-07225-Z

Comparative Longitudinal Serological Study of Anti-SARS-CoV-2 Antibody Profiles in People with COVID-19 MICROORGANISMS, 2023. DOI 10.3390/MICROORGANISMS11081985

Comparative B cell and antibody responses induced by adenoviral vectored and mRNA vaccines against COVID-19 medRxiv, 2023. DOI 10.1101/2023.06.02.23290871

Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine EBIOMEDICINE, 2023. DOI 10.1016/J.EBIOM.2023.104574

Antibody titres elicited by the 2018 seasonal inactivated influenza vaccine decline by 3 months post-vaccination but persist for at least 6 months INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2023. DOI 10.1111/IRV.13072

Ancestral, Delta, and Omicron (BA.1) SARS-CoV-2 strains are dependent on serine proteases for entry throughout the human respiratory tract MED, 2023. DOI 10.1016/J.MEDJ.2023.08.006

A placental model of SARS-CoV-2 infection reveals ACE2-dependent susceptibility and differentiation impairment in syncytiotrophoblasts NATURE CELL BIOLOGY, 2023. DOI 10.1038/S41556-023-01182-0

What influenza activity can we anticipate in 2022? MEDICAL JOURNAL OF AUSTRALIA, 2022. DOI 10.5694/MJA2.51437

The 2018 annual cost burden for children under five years of age hospitalised with respiratory syncytial virus in Australia COMMUNICABLE DISEASES INTELLIGENCE, 2022. DOI 10.33321/CDI.2022.46.5

Temporal differences in culturable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) from the respiratory and gastrointestinal tracts in a patient with moderate coronavirus disease 2019 (COVID-19) INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY, 2022. DOI 10.1017/ICE.2021.223

Sequential Transmission of Influenza Viruses in Ferrets Does Not Enhance Infectivity and Does Not Predict Transmissibility in Humans MBIO, 2022. DOI 10.1128/MBIO.02540-22

SARS-CoV-2 Omicron BA.1 Challenge after Ancestral or Delta Infection in Mice EMERGING INFECTIOUS DISEASES, 2022. DOI 10.3201/EID2811.220718

Robustness of the Ferret Model for Influenza Risk Assessment Studies: a Cross-Laboratory Exercise MBIO, 2022. DOI 10.1128/MBIO.01174-22

Robust and prototypical immune responses towards COVID-19 BNT162b2 vaccines in Indigenous people JOURNAL OF IMMUNOLOGY, 2022. DOI 10.4049/JIMMUNOL.208.SUPP.65.13

Preclinical and clinical developments for combination treatment of influenza PLOS PATHOGENS, 2022. DOI 10.1371/JOURNAL.PPAT.1010481

Opposing Effects of Prior Infection versus Prior Vaccination on Vaccine Immunogenicity against Influenza A(H3N2) Viruses VIRUSES-BASEL, 2022. DOI 10.3390/V14030470

Off-target effects of bacillus Calmette-Guerin vaccination on immune responses to SARS-CoV-2: implications for protection against severe COVID-19 CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2022. DOI 10.1002/CTI2.1387

Nonhuman primate models for evaluation of SARS-CoV-2 vaccines EXPERT REVIEW OF VACCINES, 2022. DOI 10.1080/14760584.2022.2071264

Long-read RNA sequencing identifies polyadenylation elongation and differential transcript usage of host transcripts during SARS-CoV-2 <italic>in vitro</italic> infection bioRxiv, 2022. DOI 10.1101/2021.12.14.472725

Long-Read RNA Sequencing Identifies Polyadenylation Elongation and Differential Transcript Usage of Host Transcripts During SARS-CoV-2 <i>In Vitro</i> Infection FRONTIERS IN IMMUNOLOGY, 2022. DOI 10.3389/FIMMU.2022.832223

Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects JOURNAL OF VIROLOGY, 2022. DOI 10.1128/JVI.01110-21

Integrated immune networks in SARS-CoV-2 infected pregnant women reveal differential NK cell and unconventional T cell activation JOURNAL OF IMMUNOLOGY, 2022. DOI 10.4049/JIMMUNOL.208.SUPP.125.10

Heparin Inhibits SARS-CoV-2 Replication in Human Nasal Epithelial Cells VIRUSES-BASEL, 2022. DOI 10.3390/V14122620

Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020 ANTIVIRAL RESEARCH, 2022. DOI 10.1016/J.ANTIVIRAL.2022.105281

Fibrin clot characteristics and anticoagulant response in a SARS-CoV-2-infected endothelial model EJHAEM, 2022. DOI 10.1002/JHA2.407

Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2 FRONTIERS IN IMMUNOLOGY, 2022. DOI 10.3389/FIMMU.2022.889372

Enhanced metanephric specification to functional proximal tubule enables toxicity screening and infectious disease modelling in kidney organoids NATURE COMMUNICATIONS, 2022. DOI 10.1038/S41467-022-33623-Z

Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model MBIO, 2022. DOI 10.1128/MBIO.01056-22

Correlates of protection, thresholds of protection, and immunobridging in SARS-CoV-2 infection medRxiv, 2022. DOI 10.1101/2022.06.05.22275943

Comparison of Seroconversion in Children and Adults With Mild COVID-19 JAMA NETWORK OPEN, 2022. DOI 10.1001/JAMANETWORKOPEN.2022.1313

Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2 ISCIENCE, 2022. DOI 10.1016/J.ISCI.2022.105259

Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine ACS NANO, 2022. DOI 10.1021/ACSNANO.2C04543

Age-related differences in SARS-CoV-2 binding factors: An explanation for reduced susceptibility to severe COVID-19 among children? PAEDIATRIC RESPIRATORY REVIEWS, 2022. DOI 10.1016/J.PRRV.2022.01.008

ACE2 Expression in Organotypic Human Airway Epithelial Cultures and Airway Biopsies FRONTIERS IN PHARMACOLOGY, 2022. DOI 10.3389/FPHAR.2022.813087

A new route to vaccines using PROTACs NATURE BIOTECHNOLOGY, 2022. DOI 10.1038/S41587-022-01406-Y

Where I work Kendall Powell NATURE, 2021. DOI 10.1038/D41586-021-01175-9

What level of neutralising antibody protects from COVID-19? . medRxiv, 2021. DOI 10.1101/2021.03.09.21252641

Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteers CLINICAL INFECTIOUS DISEASES, 2021. DOI 10.1093/CID/CIAA1290

Vaccines for older adults BMJ-BRITISH MEDICAL JOURNAL, 2021. DOI 10.1136/BMJ.N188

Transcriptional and epi-transcriptional dynamics of SARS-CoV-2 during cellular infection CELL REPORTS, 2021. DOI 10.1016/J.CELREP.2021.109108

The threat of zoonotic coronaviruses MICROBIOLOGY AUSTRALIA, 2021. DOI 10.1071/MA21003

The success of SARS-CoV-2 vaccines and challenges ahead CELL HOST & MICROBE, 2021. DOI 10.1016/J.CHOM.2021.06.016

Symptoms and laboratory manifestations of mild COVID-19 in a repatriated cruise ship cohort EPIDEMIOLOGY & INFECTION, 2021. DOI 10.1017/S0950268821000315

Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay JCI INSIGHT, 2021. DOI 10.1172/JCI.INSIGHT.150012

Science, not speculation, is essential to determine how SARS-CoV-2 reached humans LANCET, 2021. DOI 10.1016/S0140-6736(21)01419-7

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial LANCET INFECTIOUS DISEASES, 2021. DOI 10.1016/S1473-3099(21)00200-0

SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection PLOS PATHOGENS, 2021. DOI 10.1371/JOURNAL.PPAT.1010175

SARS-CoV-2 Variants and Vaccines NEW ENGLAND JOURNAL OF MEDICINE, 2021. DOI 10.1056/NEJMSR2105280

Robust correlations across six SARS-CoV-2 serology assays detecting distinct antibody features CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2021. DOI 10.1002/CTI2.1258

Reduced seroconversion in children compared to adults with mild COVID-19 medRxiv, 2021. DOI 10.1101/2021.10.17.21265121

Prevalence of Neutralising Antibodies to HCoV-NL63 in Healthy Adults in Australia VIRUSES-BASEL, 2021. DOI 10.3390/V13081618

Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2 CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2021. DOI 10.1002/CTI2.1269

Persistence of SARS-CoV-2-Specific IgG in Children 6 Months After Infection, Australia EMERGING INFECTIOUS DISEASES, 2021. DOI 10.3201/EID2708.210965

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection NATURE MEDICINE, 2021. DOI 10.1038/S41591-021-01377-8

Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021. DOI 10.1073/PNAS.2101918118

Maturation-Enhanced Proximal Tubules Enable Functionality, Toxicity Screening, and Infectious Disease Modeling in Kidney Organoids JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021.

Longitudinal evaluation of laboratory-based serological assays for SARS-CoV-2 antibody detection PATHOLOGY, 2021. DOI 10.1016/J.PATHOL.2021.05.093

Live Attenuated Cold-Adapted Influenza Vaccines COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2021. DOI 10.1101/CSHPERSPECT.A038653

Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain CELL REPORTS, 2021. DOI 10.1016/J.CELREP.2021.109822

Integrated immune dynamics define correlates of COVID-19 severity and antibody responses CELL REPORTS MEDICINE, 2021. DOI 10.1016/J.XCRM.2021.100208

Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques NATURE COMMUNICATIONS, 2021. DOI 10.1038/S41467-021-21665-8

Immune imprinting and SARS-CoV-2 vaccine design TRENDS IN IMMUNOLOGY, 2021. DOI 10.1016/J.IT.2021.09.001

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19 NATURE COMMUNICATIONS, 2021. DOI 10.1038/S41467-021-21444-5

Evaluation of 6 Commercial SARS-CoV-2 Serology Assays Detecting Different Antibodies for Clinical Testing and Serosurveillance OPEN FORUM INFECTIOUS DISEASES, 2021. DOI 10.1093/OFID/OFAB239

BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection CELL, 2021. DOI 10.1016/J.CELL.2021.03.026

BCG vaccination to reduce the impact of COVID-19 in healthcare workers: Protocol for a randomised controlled trial (BRACE trial) BMJ OPEN, 2021. DOI 10.1136/BMJOPEN-2021-052101

An iTSC-derived placental model of SARS-CoV-2 infection unveils ACE2-dependent susceptibility in syncytiotrophoblasts bioRxiv, 2021. DOI 10.1101/2021.10.27.465224

A second external quality assessment of isolation and identification of influenza viruses in cell culture in the Asia Pacific region highlights improved performance by participating laboratories JOURNAL OF CLINICAL VIROLOGY, 2021. DOI 10.1016/J.JCV.2021.104907

A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2 EBIOMEDICINE, 2021. DOI 10.1016/J.EBIOM.2021.103729

A lateral flow assay to detect neutralising antibodies against SARS-CoV-2 EUROPEAN JOURNAL OF IMMUNOLOGY, 2021.

A case report describing the immune response of an infant with congenital heart disease and severe COVID-19 COMMUNICATIONS MEDICINE, 2021. DOI 10.1038/S43856-021-00047-7

A Randomized Trial of Two 2-Dose Influenza Vaccination Strategies for Patients Following Autologous Hematopoietic Stem Cell Transplantation CLINICAL INFECTIOUS DISEASES, 2021. DOI 10.1093/CID/CIAA1711